KUALA LUMPUR: Shares and warrants of Sunzen Group Bhd were actively traded in the morning session, rising 27.27 per cent and 15.79 per cent respectively.
The diversified biotechnology and wellness company's share price surged as much as 7.5 sen to 35 sen in early trade, its highest in over a year.
By 10.18am, the stock retraced some gains to 29.5 sen, still up two sen or 7.27 per cent, with 4.47 million shares changing hands. It was the counter's busiest session in more than four months.
At that price, which also marks its highest since March 14, Sunzen commanded a market capitalisation of RM243.75 million.
However, he firm, formerly known and Sunzen Biotech, remains down 12.70 per cent year to date, based on its latest closing price of 27.5 sen yesterday.
Meanwhile, Sunzen-WC topped Bursa Malaysia's company warrants most active list after climbing as high as 11 sen, a level last seen on Feb 25.
At 10.28am, the warrants were unchanged at 9.5 sen with 12.45 million units traded, the highest volume since Nov 27, 2023.
Listed on Sept 21, 2022, the warrants were issued as part of a bonus issue of 356.89 million units, on the basis of one warrant for every two existing Sunzen shares.
Each Sunzen-WC warrant is exercisable into one new share at 20 sen per unit at any time until Sept 13, 2027, after which they will lapse if not exercised.
Earlier this month, Sunzen issued a total of 406,000 new shares through a mix of warrant exercises and a Share Issuance Scheme (SIS).
This included 76,000 shares at 13.95 sen under the SIS, followed by a total of 330,000 new shares from warrant conversions priced at 20 sen each.
The exercises raised Sunzen's total issued share capital to over 812.5 million shares, with minimal dilution to existing shareholders.
Sunzen in February inked a share sale agreement with Pure Nutritional Products Sdn Bhd to divest its entire equity interest in Sunzen Corporation Sdn Bhd and Sunzen Lifesciences Sdn Bhd for RM17.3 million in cash.
The disposal marked the group's exit from the animal health segment, aligning with its broader pivot toward human wellness, medical devices and financial services.
For the second quarter ended Dec 31, 2024, Sunzen reported a net profit of RM1.94 million on RM27.35 million in revenue, driven by festive-season demand for health products and initial contributions from its newly acquired medical devices unit.